Skip to main content

Featured

Understanding Your TFSA Contribution Room in 2026

A Tax‑Free Savings Account (TFSA) is one of Canada’s most flexible and powerful savings tools, but figuring out your exact contribution room can feel like solving a puzzle. A clear breakdown makes it much easier. How TFSA Contribution Room Works Your available room is made up of three parts: Annual TFSA limit for the current year Unused contribution room from previous years Withdrawals from previous years (added back the following January) For 2026, the annual TFSA limit is $7,000 . Step‑by‑Step: How to Calculate Your Room Use this simple formula: [ \text{TFSA Room} = \text{Unused Room from Prior Years} + \text{Current Year Limit} + \text{Withdrawals from Last Year} ] A quick example: Unused room from past years: $18,000 2026 limit: $7,000 Withdrawals made in 2025: $4,000 [ \text{Total Room} = 18,000 + 7,000 + 4,000 = 29,000 ] That means you could contribute $29,000 in 2026 without penalty. A Few Helpful Notes Over‑contributions lead to penalties, so it’s worth...
Post a Comment
Read more

article

Labels

A New Dawn in Alzheimer’s Prevention: The AHEAD 3-45 Study


The AHEAD 3-45 study represents a beacon of hope for individuals like Tyson Haller, who, at 60, is determined to understand and possibly prevent the onset of Alzheimer’s—a disease that claimed his father. This groundbreaking clinical trial is testing lecanemab, an FDA-approved drug that has shown promise in slowing Alzheimer’s progression in its early stages. The optimism surrounding this trial is palpable, as it could herald a new era where Alzheimer’s is as manageable as Type 2 diabetes.

  • Family History’s Weight: Haller’s participation is driven by his family’s battle with Alzheimer’s, highlighting the emotional and proactive steps taken by those at risk.
  • Lecanemab’s Potential: The trial’s focus on lecanemab, a drug targeting beta amyloid plaques in the brain, offers a glimpse into a future where early intervention could significantly slow the disease’s impact.
  • Scientific Debate: Despite the excitement, there’s a scientific debate about beta amyloid’s role in Alzheimer’s, underscoring the complexity of finding a definitive treatment.
  • Awaiting Results: With the AHEAD and TRAILBLAZER prevention trials running until 2027 and 2029, patients, doctors, and researchers are in a state of limbo, hopeful yet uncertain of the long-term outcomes.

This study not only represents a potential turning point in Alzheimer’s research but also embodies the personal stories of those fighting to preserve their memories and identities against this relentless disease.

Labels:

Comments

Post a Comment